Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Survival, Costs with First-Line Pazopanib Studied

Adv Ther; 2017 Nov; Vogelzang, Pal, Ghate, et al

Elderly patients with renal cell carcinoma (RCC) treated with first-line pazopanib survived longer than those who received sunitinib, according to an analysis involving >1,000 individuals. Pazopanib treatment also resulted in lower costs and utilization. Participants with RCC were ≥65 years of age and started first-line treatment with either pazopanib (n=522) or sunitinib (n=522). Investigators looked at overall survival, costs, and utilization. Among the results:

  • The group taking pazopanib survived an average of 18.2 months, vs 14.6 months in the contingent receiving sunitinib.
  • All-cause costs were ~$8,800 and ~$10,400, respectively.
  • Inpatient costs were ~$1,500 and ~$2,500, respectively.
  • Inpatient admissions and lengths of inpatient stay were lower in the pazopanib group.
Citation:

Vogelzang N, Pal S, Ghate S, et al. Clinical and economic outcomes in elderly advanced renal cell carcinoma patients starting pazopanib or sunitinib treatment: A retrospective Medicare claims analysis. Adv Ther. 2017;34(11):2452-2465. doi:10.1007/s12325-017-0628-2.

This Week's Must Reads

Older patients with ccRCC may respond better to treatment than younger patients, Feulner et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.11.006.

ccRCC with papillary features best classified as a rare morphologic variant of ccRCC, Alaghehbandan R et al. Ann Diagn Pathol. 2018 Nov 22. doi: 10.1016/j.anndiagpath.2018.11.004.

SRS can effectively control brain metastases in patients with RCC, Wardak Z et al. Clin Genitourin Cancer. 2018 Nov 20. doi: 10.1016/j.clgc.2018.11.006.

Still no validated biomarkers to select RCC treatment, D’Avella C et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.10.027

DSS of ccRCC patients lower with high hTERT, Zanjani LS et al. Pathology. 2018 Nov 19. doi: 10.1016/j.pathol.2018.08.019.

Must Reads in Renal Cell Carcinoma

Older patients with ccRCC may respond better to treatment than younger patients, Feulner et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.11.006.

Still no validated biomarkers to select RCC treatment, D’Avella C et al. Urol Oncol. 2018 Nov 23. doi: 10.1016/j.urolonc.2018.10.027

DSS of ccRCC patients lower with high hTERT, Zanjani LS et al. Pathology. 2018 Nov 19. doi: 10.1016/j.pathol.2018.08.019.

ccRCC with papillary features best classified as a rare morphologic variant of ccRCC, Alaghehbandan R et al. Ann Diagn Pathol. 2018 Nov 22. doi: 10.1016/j.anndiagpath.2018.11.004.

SRS can effectively control brain metastases in patients with RCC, Wardak Z et al. Clin Genitourin Cancer. 2018 Nov 20. doi: 10.1016/j.clgc.2018.11.006.